We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-9.61%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$216M
AUM Growth
-$53.3M
Cap. Flow
-$20.8M
Cap. Flow %
-9.59%
Top 10 Hldgs %
56.68%
Holding
66
New
2
Increased
13
Reduced
15
Closed
8
Avg Time Held
1.4 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.88M
2
CELG
Celgene Corp
CELG
+$2.71M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$2.33M
4
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$2.24M
5
AMRN icon
Amarin Corp
AMRN
+$2.13M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$6.97M
2
EXEL icon
Exelixis
EXEL
+$6.88M
3
GTHX icon
G1 Therapeutics, Inc. Common Stock
GTHX
+$4.25M
4
SAGE icon
Sage Therapeutics
SAGE
+$3.01M
5
BIIB icon
Biogen
BIIB
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GILD icon
1
Gilead Sciences
GILD
$195B
$20M 9.26%
316,284
– –
2016 Q4
11 quarters
CELG
2
DELISTED
Celgene Corp
CELG
$17M 7.85%
171,022
+28,500
+20% +$2.71M
2016 Q4
11 quarters
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$129B
$14.2M 6.58%
84,022
-1,000
-1% -$177K
2016 Q4
11 quarters
NBIX icon
4
Neurocrine Biosciences
NBIX
$13.9B
$13.3M 6.13%
147,300
-9,500
-6% -$888K
2017 Q3
8 quarters
AMGN icon
5
Amgen
AMGN
$235B
$12.8M 5.9%
66,000
– –
2018 Q4
3 quarters
REGN icon
6
Regeneron Pharmaceuticals
REGN
$82B
$11.1M 5.11%
39,830
+16,500
+71% +$4.88M
2016 Q4
11 quarters
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$10M 4.62%
102,141
+3,500
+4% +$395K
2016 Q4
11 quarters
STML
8
DELISTED
Stemline Therapeutics, Inc.
STML
$8.7M 4.02%
835,245
+91,000
+12% +$1.19M
2017 Q1
10 quarters
PTCT icon
9
PTC Therapeutics
PTCT
$5.09B
$7.98M 3.69%
236,000
-23,000
-9% -$1M
2019 Q1
2 quarters
ILMN icon
10
Illumina
ILMN
$40.5B
$7.64M 3.53%
25,803
– –
2018 Q2
5 quarters
BIIB icon
11
Biogen
BIIB
$34.8B
$7.38M 3.41%
31,700
-11,000
-26% -$2.56M
2018 Q4
3 quarters
INCY icon
12
Incyte
INCY
$23B
$7.16M 3.31%
96,500
+17,500
+22% +$1.41M
2016 Q4
11 quarters
INSM icon
13
Insmed
INSM
$21.7B
$6.29M 2.91%
356,600
– –
2019 Q1
2 quarters
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.94M 2.74%
218,000
+90,000
+70% +$2.33M
2016 Q4
11 quarters
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$10.8B
$5.88M 2.72%
87,284
+23,000
+36% +$1.77M
2016 Q4
11 quarters
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$5.67M 2.62%
66,400
+5,500
+9% +$403K
2017 Q1
10 quarters
AMRN icon
17
Amarin Corp
AMRN
$244M
$3.93M 1.81%
12,950
+6,100
+89% +$2.13M
2018 Q4
3 quarters
SGMO icon
18
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.17M 1.46%
350,000
+200,000
+133% +$2.24M
2017 Q3
8 quarters
IONS icon
19
Ionis Pharmaceuticals
IONS
$7.33B
$2.77M 1.28%
46,181
-36,600
-44% -$2.39M
2017 Q1
10 quarters
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$31.3B
$2.71M 1.25%
33,800
– –
2017 Q3
8 quarters
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$3.4B
$2.45M 1.13%
68,000
+15,000
+28% +$455K
2018 Q3
4 quarters
GWPH
22
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.28M 1.05%
19,800
+8,800
+80% +$1.34M
2017 Q4
7 quarters
SAGE icon
23
DELISTED
Sage Therapeutics
SAGE
$2.25M 1.04%
16,000
-17,996
-53% -$3.01M
2016 Q4
11 quarters
ABMD
24
DELISTED
Abiomed Inc
ABMD
$2.08M 0.96%
11,700
– –
2018 Q2
5 quarters
KALV icon
25
DELISTED
KalVista Pharmaceuticals
KALV
$2.06M 0.95%
177,433
-10,166
-5% -$164K
2016 Q4
11 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2019 Portfolio in Review

As of Q3 2019, International Biotechnology Trust held 66 positions worth $216M, down 20% from $270M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust withdrew a net $20.8M in Q3 2019, closing 8 positions and reducing 15 holdings. Its most notable exit was Iovance Biotherapeutics, an estimated $2.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Deciphera Pharmaceuticals, Inc. Common Stock worth $577K.

  • International Biotechnology Trust's largest Q3 2019 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 17,000 shares worth $577K.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q3 2019, an estimated $4.88M increase.
  • International Biotechnology Trust's biggest Q3 2019 reduction was Halozyme, cutting an estimated $6.97M.
  • International Biotechnology Trust fully exited Iovance Biotherapeutics in Q3 2019, selling an estimated $2.54M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $216M portfolio in Q3 2019.
  • International Biotechnology Trust opened 2 new positions and closed 8 in Q3 2019.
  • International Biotechnology Trust's portfolio value fell 20% quarter-over-quarter to $216M.

Based on International Biotechnology Trust's 13F filing for Q3 2019, filed 14 Nov 2019.